This report describes an open-label, nonrandomized, prospective evaluation of the effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy on patients who have Fabry disease and also received enzyme replacement therapy with agalsidase-␤, given at 1 mg/kg body wt every 2 wk. Previous placebo-controlled phase III and phase IV trials with agalsidase-␤ demonstrated clearing of globotriaosylceramide from vascular endothelia but little effect on proteinuria or progressive loss of kidney function in patients with Fabry disease and severe chronic kidney disease marked by overt proteinuria and/or estimated GFR Ͻ60 ml/min per 1.73 m 2 . Angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker therapy is the standard of care for patients with proteinuric kidney diseases, but their use is challenging in patients with Fabry disease and low or low-normal baseline systemic BP. A group of patients with Fabry disease were treated with antiproteinuric therapy, in conjunction with agalsidase-␤; sustained reductions in proteinuria with stabilization of kidney function were achieved in a group of six patients who had severe Fabry nephropathy; the progression rate was Ϫ0.23 Ϯ 1.12 ml/min per 1.73 m 2 per yr with 30 mo of follow-up.
giotensin receptor blocker (ARB) therapy as the treatment of choice for overt proteinuria, which is an important factor in the progression of CKD. Systolic BP Ͻ130 mmHg is recommended if the urine protein/creatinine ratio is Ͼ0.5 g/g in CKD 14 or the urine albumin/creatinine ratio is Ͼ500 mg/g in diabetic kidney disease. 15 These clinical practice recommendations are challenging in Fabry nephropathy, because many patients have relatively normal or low BP in the early stages of their disease. 1, 16 The objective of our study was to describe the effects of ACEI/ARB therapy on urinary protein excretion in patients who had Fabry disease and were treated with ERT. The hypothesis was that reduction of proteinuria with ACEI/ARB therapy in conjunction with ERT would be associated with slowing of the progressive decline of eGFR, especially in high-risk patients who had proteinuria and initial eGFR rates Ͻ60 ml/min per 1.73 m 2 . Our patients tolerated ACEI/ARB therapy and had sustained reductions in BP and proteinuria and eGFR stabilization compared with previous experiences with similar patients who were treated with ERT alone. [7] [8] [9] [10] 12 
RESULTS

Patient Characteristics
The median age for the eight mens and three women was 37.1 yr (range 18.3 to 56.7) at the time ERT was begun. Nine families with seven distinct mutations were represented, and there were two relative pairs: Mother (patient 10) and son (patient 8), and brother (patient 6) and brother (patient 7; Table 1 ). The clinical manifestations were diverse, with multiple organ system involvement in addition to Fabry nephropathy. Some patients had hyperlipidemia, coronary artery disease, and hypertension, in addition their Fabry disease ( Table 1) .
Timing of ACEI/ARB and Agalsidase-␤ Therapy
Most patients were begun on ACEI/ARB therapy before starting ERT. The subsequent duration of ERT is shown in Table 1 (mean 30.3 Ϯ 9.8 mo; median 30.1 mo; range 16 to 43; excludes patient 11). Some patients received both ACEI and ARB; the dosages were adjusted empirically, depending on the baseline proteinuria, the response to antiproteinuric therapy, and tolerance of the antihypertensive effects of ACEI/ARB therapy. Other agents that could affect kidney function and proteinuria are also listed in Table 1 .
Two of the patients participated in the previous phase IV study of agalsidase-␤ 8 ; patient 9 was randomly assigned to the active treatment arm throughout the phase IV study, whereas patient 10 received placebo during the blinded phase and went on to open-label treatment with agalsidase-␤ after having sustained ventricular tachycardia. Three patients were previously 2 and urine protein/creatinine ratio 3.54 g/g) developed acute pancreatitis as a result of pancreas divisum, acute cholecystitis with cholecystectomy, and subacute bacterial endocarditis and required acute dialysis soon after the start of ERT. His kidney function slightly improved, but his urine protein excretion remained elevated and chronic dialysis was needed within 6 mo of starting ERT. His data are presented in the figures but are not included in the summary statistics for evaluation of the effects of ACEI/ARB therapy on urine protein/creatinine ratio or the eGFR progression rate. Two other male patients also had laparoscopic cholecystectomy during the observation period, but these events were deemed to be coincidental and not related to ERT.
Systemic BP, Urine Protein/Creatinine Ratios, and eGFR
The four patients with stages 1 and 2 CKD were younger (mean 33.8 Ϯ 11.8 yr) than the seven patients with stages 3 and 4 CKD (mean 42.2 Ϯ 11.4 yr; Table 1 ). As shown in Table 2 , the baseline BP were higher for the patients with stages 3 and 4 CKD than for the patients with stages 1 and 2 CKD (135/82 and 98/63 mmHg, respectively). ERT was started 7.3 Ϯ 6.4 mo (median 4.9; range 0.3 to 20.6) after initiation of ACEI/ARB therapy. At that point, the BP were decreased by ACEI/ARB therapy, especially for patients with stages 3 and 4 CKD, and these effects were sustained throughout the period of follow-up ( Table 2 ). The average BP measurements relative to the start of ERT are shown in Figure 1 . Despite more aggressive ACEI/ARB therapy, the BP in the patients with stages 3 and 4 remained higher than the BP in patients with stages 1 and 2 CKD. The urinary protein/creatinine ratios are shown in Table 2 ; three of the patients with stages 1 and 2 CKD had overt proteinuria (Ն0.3 g/g) at baseline. The median urinary protein/ creatinine ratio was 0.36 (range 0.17 to 0.46) for the patients with stages 1 and 2 CKD and 1.24 (range 0.23 to 6.3) for patients with stages 3 and 4 CKD, excluding patient 11. ACEI/ ARB treatment reduced the median urinary protein/creatinine ratio for patients with stages 3 and 4 CKD to 0.21 (range 0.1 to 1.6) and for patients with stages 1 and 2 CKD to 0.22 (range 0.07 to 0.37; Table 2 ). The individual urinary protein/creatinine ratios at baseline, at initiation of ERT, and throughout the observation period are shown in Figure 2 . Higher baseline urine protein/creatinine ratios and sustained reductions were more evident in patients with stages 3 and 4 CKD ( Figure 2B ) than in patients with stages 1 and 2 CKD (Figure 2A) . Two of these patients (5 and 8 in Figure 2A ) had initial decreases in their urine protein/creatinine ratios that were not sustained because they chose to stop or reduce their ACEI/ARB therapy during the observation period.
The regressions of urine protein/creatinine ratios over time are presented in Table 3 . The second column represents the baseline ratio for each patient obtained at the time that ACEI/ ARB therapy was started. The third column represents the intercept value, corresponding to the point at which ERT was started in each patient. The duration of follow-up on ERT and the number of complete evaluations for each patient are also presented in Table 3 .
The baseline urine protein/creatinine ratio was 0.34 Ϯ 0.13 (median 0.36) for patients with stages 1 and 2 CKD, and this ratio was significantly different from the regression intercept (0.22 Ϯ 0.12; median 0.22). The baseline urine protein/creatinine ratio was 1.91 Ϯ 2.29 (median 1.24) for patients with stages 3 and 4 CKD, and this ratio was also significantly different from the regression intercept (0.30 Ϯ 0.38; median 0.15), which reflects the antiproteinuric effects of ACEI/ARB therapy. The regression slopes for both groups were not significantly different from zero, indicating that the reductions in urine protein/creatinine ratio were maintained throughout the observation period. Urine protein and urine albumin measurements are shown in Table 4 . Albumin excretion accounted for approximately half of the total urinary protein excretion and was reduced in parallel with total protein by ACEI/ARB therapy.
The individual regressions of eGFR for each patient are presented in Figure 3 , and the results are presented in Table 5 . The second column presents the baseline eGFR obtained when ACEI/ARB therapy was started, and the third column presents the intercept, corresponding to the point at which ERT was started in each patient. The initial eGFR was 108 Ϯ 10.8 ml/min per 1.73 m 2 for patients with stages 1 and 2 CKD and was reduced to 96.9 Ϯ 17.2 ml/min per 1.73 m 2 by ACEI/ARB therapy ( Table  2 ). The initial eGFR was 52.0 Ϯ 16.5 ml/min per 1.73 m 2 for patients with stages 3 and 4 CKD and was significantly reduced to 39.4 Ϯ 10.9 ml/min per 1.73 m 2 by ACEI/ARB therapy ( Table 2) . As was seen in other forms of proteinuric kidney disease, 17 eGFR was initially reduced by ACEI/ARB therapy as BP was lowered.
Excluding the initial change in eGFR before ERT was begun, the average progression rate for patients with stages 1 and 2 CKD was 1.18 Ϯ 2.78 ml/min per 1.73 m 2 per yr and Ϫ0.23 Ϯ 1.12 ml/min per 1.73 m 2 per yr for patients with stages 3 and 4 CKD. The individual regressions are presented in Table 5 , and the averaged values for both groups are presented in Figure 4 . The slopes for both groups were not significantly different c Zero time assigned to the point at which ERT was initiated. d P ϭ 0.0161, two-tailed t test, comparing fourth-root transformation of regression intercept to initial P/C ratio. e P ϭ 0.0054, two-tailed t test, comparing fourth-root transformation of regression intercept to initial P/C ratio.
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DISCUSSION
Our results demonstrate the feasibility of using ACEI/ARB therapy in patients with Fabry nephropathy, most of whom are not overtly hypertensive. The patients tolerated ACEI/ARB therapy and had sustained reductions of urinary protein excretion (Table 1, Figure 2 ). The progression rate for patients with stages 3 and 4 CKD (0.22 Ϯ 1.47 ml/min per 1.73 m 2 per yr) is better than previously described in patients who had moderately severe Fabry nephropathy and who were treated ERT but did not receive antiproteinuric therapy. [7] [8] [9] [10] 12 Agalsidase-␤ given at 1 mg/kg had no evident effect on urinary protein excretion in patients with Fabry disease in an open-label study, 9 in placebo-controlled double blind phase III 4,5 and phase IV trials, 8 and in an open-label extension of the phase III trial. 10 Agalsidase-␣, at the usual dosage of 0.2 mg/kg, did not reduce proteinuria. 7, 12 Although weekly infusions may have slowed progression compared with infusions every 2 wk, agalsidase-␣ still did not affect proteinuria. 12 Relatively low systemic BP was described early as a feature of Fabry disease. 16 Nevertheless, the use of antiproteinuric therapy has been recommended for treatment of Fabry disease with kidney involvement. 18, 19 ACEI/ARB therapy reduced systemic BP in our patients with Fabry nephropathy, but our approach is consistent with the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines for proteinuric kidney disease, 14, 15 in which the goal of reducing urine protein excretion to Ͻ500 mg/d is recommended even if systolic BP falls below 130 mmHg. BP reductions in patients with stages 3 and 4 CKD did limit the total dosing of ACEI/ARB therapy but was generally well tolerated. No serious adverse events were observed during this study other than occasional hypotensive symptoms that quickly responded to reductions in the dosage of the ACEI/ARB therapy and mild episodes of hyperkalemia. Whereas the reduction in BP in patients with stages 3 and 4 CKD was evident, the systolic pressures were not reduced below that observed in patients with stages 1 and 2 CKD before ACEI/ARB therapy was started (Table 2, Figure 1) .
Previous reports documented the progressive course of Fabry nephropathy. Branton et al. 1 reported that 14 male patients developed "chronic renal insufficiency" with a progression rate of Ϫ12.2 Ϯ 9.1 ml/min per yr. Breunig et al. 9 described 26 patients who were treated with agalsidase-␤. Eight patients with stage 2 or 3 CKD (baseline GFR 71 Ϯ 17 ml/min per 1.73 m 2 ) showed progressive deterioration of their GFR to 60 Ϯ 23 ml/min per 1.73 m 2 during a 26.4-mo follow-up period, with an apparent progression rate of Ϫ4.7 Ϯ 5.4 ml/min per 1.73 m 2 per yr. Fourteen patients received ACEI/ARB therapy, but there were no effects on BP or proteinuria with the dosages that were used.
Banikazemi et al. 8 reported a prospective, placebo-controlled trial of agalsidase-␤ in patients with Fabry disease and mild to moderate kidney disease. The baseline eGFR in the treatment group was 53 Ϯ 18 ml/min per 1.73 m 2 , and BP was 126 Ϯ 16 mmHg (systolic) and 77 Ϯ 10 mmHg (diastolic). The baseline urine protein/creatinine ratios were 1.5 Ϯ 1.0, similar to what we observed for patients with Fabry disease and stages 3 and 4 CKD, before the institution of ACEI/ ARB therapy ( Table 2) . Some of the patients did received ACEI/ARB therapy, but there was no systematic effort to reduce urinary protein excretion. The final BP were 121 Ϯ 15 mmHg (systolic) and 72 Ϯ 10 mmHg (diastolic), and the final urine protein/creatinine ratios were 1.4 Ϯ 1.6, 8 values that are much higher than we report for our patients with stages 3 and 4 CKD and Fabry disease at the end of the 30-mo follow-up period (Table 2) .
A phase III extension study with agalsidase-␤ has been reported 10 ; minimal rates of progression during a 5-yr follow-up period were seen patients who did not initially have overt proteinuria. Of note, a subset of patients who had normal initial eGFR but had glomerulosclerosis in 50% of their glomeruli and/or proteinuria Ͼ1 g/d had rapid decline of their eGFR. 10 Schiffmann et al. 12 described 14 patients with overt baseline proteinuria; 11 were switched from bimonthly to weekly infusions of agalsidase-␣ and followed for 24 mo. At the switch, mean eGFR was 53.7 Ϯ 20.9 ml/min per 1.73 m 2 , and mean rate of progression was Ϫ8.0 Ϯ 2.7 ml/min per 1.73 m 2 per yr. With weekly dosing of agalsidase-␣, the progression rate was Ϫ3.3 Ϯ 4.6 ml/min per 1.73 m 2 /yr, but urinary protein excretion remained the same. The improved progression rate suggests an effect of increasing the dosage of ERT, as has previously been noted, 11, 13 but these progression rates are greater than reported herein with agalsidase-␤ and ACEI/ARB therapy.
The importance of BP control 17, 20, 21 and the renal protective effects of antiproteinuric therapy have received well-deserved attention. [22] [23] [24] [25] [26] The primary effect is undoubtedly due to reductions in BP, but other, nonhemodynamic effects may account for improved outcomes with ACEI/ARB compared other antihypertensive agents.
We have applied this approach for reducing proteinuria to patients who had Fabry nephropathy and were also being treated with agalsidase-␤. Our earlier experience suggested that the beneficial effects of ACEI/ARB therapy on eGFR progression requires optimal dosing of ERT; we would not expect ACEI/ARB therapy to slow eGFR progression in the absence or with suboptimal dosages of ERT. 11 Schiffmann et al. 12 recently confirmed this conclusion that 0.2 mg/kg body wt agalsidase-␣ given every 2 wk is not an effective dosage of ERT for treating moderately severe Fabry nephropathy.
Although ACEI/ARB therapy reduced systemic BP, the urinary protein/creatinine ratios were reduced to Յ0.5 g/g. The achieved systemic BP levels were similar in our patients with stages 3 and 4 CKD to patients with stages 1 and 2 CKD before or after institution of ACEI/ARB therapy and were reasonably well tolerated without any serious adverse events. This approach is similar to that recently proposed for treating diabetic nephropathy, 26 with the goal of reducing urinary protein excretion to Յ0.5 g/d, rather than simply lowering systemic BP to a preset target level.
Confirmation of our single-center experience with a larger group of patients in a multicenter study is under way, using combined agalsidase-␤ and ACEI/ARB therapy in which the primary treatment effect will be sustained reduction in urinary protein/ creatinine ratio Յ0.5 g/g, with the primary outcome measure being the rate of progression of eGFR. 13, 27 
CONCISE METHODS
Patient Selection and Treatment
We describe the first group of patients who had Fabry disease and were treated at UAB with agalsidase-␤ (Fabrazyme; Genzyme Corp., Cambridge MA), given intravenously at 1 mg/kg body wt every 2 wk. Four male patients who had kidney transplants before starting ERT and were not expected to have any effect of ERT on their kidney function are excluded from this report. 28 The 30-mo observation period was a priori chosen to extend 12 mo beyond the median follow-up period of the phase IV study of agalsidase-␤ therapy. 8 The patients were seen on a regular basis in our outpatient clinic and received standard clinical care for patients with CKD. 14, 29 After initial evaluation, the patients were started on ACEI/ARB therapy for proteinuria. After confirmation of their eligibility, ERT treatment was begun with agalsidase-␤. Various infusion centers were used, all of which were separate from the UAB Fabry Clinic. Proteinuria, albuminuria, and urine creatinine were measured in 24-h urine collections at the initial evaluation and at nearly all subsequent visits. All patients signed consents approved by the UAB institutional review board (X050202007) and were enrolled in the Fabry registry (https://www.lsdregistry-.net/fabryregistry/). This open-label observational study was registered at http://ClinicalTrials.gov (NCT00343577).
Data Presentation and Analyses
The primary goal was to determine the tolerability of ACEI/ARB therapy in dosages that would minimize the urinary protein/creatinine ratio in Fabry nephropathy. The eGFR rate of decline was the out- come measure. The Modification of Diet in Renal Disease (MDRD) eGFR equation used serum creatinine, gender, and age (all participants were white). 30 Nearly all of the laboratory tests were performed at the UAB Clinical Laboratory; the creatinine method has been "calibrated." 30 The progression rate (ml/min per 1.73 m 2 per yr) was calculated as the regression slope of the eGFR obtained at each patient's follow-up visit. The tables present data obtained before initiation of ACEI/ARB therapy, at the clinic visit closest to the start of agalsidase-␤ therapy, at the clinic visits closest to 6 and, 18 mo, and at the last available clinic visit for each patient. The figures present individual patient regressions for urine protein/creatinine ratio and eGFR.
The first patient was seen on August 27, 2001 , and the last patient entered the study on October 24, 2004 . The final visits occurred on December 11, 2006 . The patients were treated with ACEI/ARB therapy for 7.3 Ϯ 6.4 mo (median 5.2 mo; range Ϫ20.6 to 0) before starting ERT. The average duration of follow-up was 30.3 Ϯ 9.8 mo (median 30.1 mo; range 16 to 43) after starting ERT for the 10 patients who could be fully analyzed. To facilitate comparison with the phase IV trial, 8 we divided the patients into two groups on the basis of the initial eGFR: Four patients with eGFR Ͼ60 ml/min per 1.73 m 2 (stages 1 and 2 CKD) and seven patients with eGFR Յ60 ml/min per 1.73 m 2 (stages 3 and 4 CKD). Standard methods were used for descriptive statistics, comparison of means, and regression analyses (Microsoft Excel, Office 2004 for Macintosh; Microsoft, Redmond, WA). Normal distributions were assumed for BP and eGFR, and these were compared with two-tailed paired t test. Urine protein excretion is not normally distributed in Fabry nephropathy, 8 so these comparisons were carried out with transformed urinary protein/creatinine ratios. The fourth-root transformation of proteinuria was used in the phase IV study 8 ; we used the same transformation because we had too few patients to assess the distribution normality independently. Linear regression analysis was performed for individual patients as well as grouped means. The intercepts of these analyses were compared with the last available determinations of urine protein/creatinine ratio and eGFR obtained before ACEI/ARB therapy was started. The regression slopes were used to evaluate the stability of urine protein/creatinine ratio and eGFR over time after ERT was begun. Significance was assumed when the calculated P values were Ͻ0.05. Descriptive data are presented as means Ϯ SD and medians (range).
